Compass Diversified Reports First Quarter 2025 Financial Results WESTPORT, Conn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market businesses, announced today its consolidated operating results for the three months ended March 31, 2025 and filed its Quarterly Report on Form 10-Q for the period. The Company expects to file its Quarterly Reports on Form 10-Q for the second and third quarters of 2025 in the coming weeks. “Today’s filing represents another important step in our efforts to bring our financial repor...
AMREP Reports Second Quarter Fiscal 2026 Results HAVERTOWN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $1,200,000, or $0.22 per diluted share, for its 2026 fiscal second quarter ended October 31, 2025 compared to net income of $4,042,000, or $0.75 per diluted share, for the same period of the prior year. For the first six months of 2026, AMREP had net income of $5,892,000, or $1.09 per diluted share, compared to net income of $8,106,000, or $1.51 per diluted share, for the same period of 2025. Revenues were $9,398,000 and $27,250,000 f...
Compass Diversified Completes Restatement of Previously Issued Financial Statements WESTPORT, Conn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market branded consumer and industrial businesses, today announced the filing of its restated financial results for fiscal years 2022, 2023, and 2024 and the financial information for each of the interim periods included within those years. “We are pleased to have completed this extensive restatement process. The financial and accounting fraud perpetrated by the former ...
Compass Diversified Announces Conference Call to Discuss the Restatement of Financial Results WESTPORT, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market branded consumer and industrial businesses, announced today that it plans to host a conference call to discuss the restatement of its financial results for fiscal years 2022, 2023, and 2024, and the unaudited financial information for each of the interim periods included within those years, on Thursday, December 4, 2025, at 5:00 p.m. ET. A live webcast ...
A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Moody's Ratings said that Compass Group Diversified Holdings LLC's (Compass) ratings remain on review for downgrade following the filing by operating subsidiary Lugano Holding, Inc. (Lugano) for chapter 11 bankruptcy protection on 16 November 2025. This follows Compass' disclosure of Lugano's financ...
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...
Compass Diversified Announces Update on Lugano Subsidiary WESTPORT, Conn., Nov. 16, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today announced that its subsidiary, Lugano Holding, Inc. (“Lugano”), has filed for Chapter 11 protection under the U.S. Bankruptcy Code. The filing was made under the direction of an independent special committee of Lugano’s Board of Directors, which determined that a Chapter 11 bankruptcy process represents the best path to maximize value for Lugano’s stakeholders. “We support the Lugano board’s decision to file for Chapter 11 as the bes...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Compass Diversified Announces Extension of Credit Agreement Forbearance WESTPORT, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) announced today that its senior secured lender group has extended to November 10, 2025 the due date for CODI to publish its restated financial results for the fiscal years ended December 31, 2022, 2023 and 2024. CODI is in active conversations with its senior lender group regarding a formal forbearance extension that will provide additional time to complete the restatement process. This extension is expected to be finalized in...
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.